Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Antiviral and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ISG20 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ISG20 Wild-Type Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic activity assays. |
View ISG20 Products |
| Mutant Control | ISG20 Exonuclease-Dead Mutant (e.g., D94G / E10A) Crucial negative control for validating exonuclease-dependent mechanisms. |
View ISG20 Products |
| Gene Delivery | ISG20 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and viral replication inhibition assays. |
View ISG20 Products |
| Validator | ISG20 siRNA Set For knock-down verification in oncology and immunological pathway studies. |
View ISG20 Products |
| Related Target A | IFNAR1 Interferon Alpha/Beta Receptor 1; upstream driver of ISG20 expression in antiviral responses. |
View IFNAR1 Products |
| Related Target B | OAS1 2'-5'-Oligoadenylate Synthetase 1; synergistic interferon-stimulated gene involved in RNA degradation. |
View OAS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Verification | Recombinant ISG20 proteins produced with strict endotoxin control and verified sequence integrity to ensure reliable 3'-5' exoribonuclease activity. |
| Off-Target Nuclease Screening | Homolog panels (TREX1, TREX2) available to screen for small-molecule inhibitor selectivity. |
| Lack of Validated Controls | Catalytically inactive mutant proteins (D94G) provided to serve as absolute negative controls. |
| False Positives in Cell Assays | Validated sequence-specific siRNA pools included to confirm target-specific phenotypes. |
Live ISG20 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic interest in ISG20 (Interferon-Stimulated Gene 20) spans two distinct frontiers: oncology and antiviral development. Historically characterized as a 3'-5' exoribonuclease that selectively degrades viral RNA, recent discoveries have highlighted its overexpression in various solid tumors (such as glioblastoma, hepatocellular carcinoma, and breast cancer). In the tumor microenvironment, ISG20 plays a non-canonical role in promoting immune evasion, tumor cell proliferation, and resistance to standard chemotherapies.
The race for ISG20 therapeutics is intensifying, with major players shifting focus from traditional interferon-based induction to targeted small-molecule inhibitors for oncology, alongside mRNA and gene therapy modalities for antiviral applications. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting the specific epitranscriptomic regulatory mechanisms of ISG20, particularly its interactions with m6A-modified RNAs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Glioblastoma, Hepatocellular Carcinoma | Selectivity Assay (Need Mutant vs WT Proteins to verify exonuclease inhibition) |
| Gene / mRNA Therapy | Antiviral Therapeutics Developers | HBV, Influenza, RNA Virus Infections | Overexpression Validation (Need Lentivirus for Stable Cell Lines) |
| Combination Biologics | Immuno-oncology Consortiums | Refractory Solid Tumors | Synergy Evaluation (Need IFNAR1 & ISG20 pathway co-validation) |